MIRA Pharmaceuticals (MIRA) Competitors $1.16 +0.02 (+2.11%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIRA vs. ADAG, IZTC, CABA, VTGN, IMAB, ANRO, PYRGF, CLSD, PYXS, and RANIShould you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Adagene (ADAG), Invizyne Technologies (IZTC), Cabaletta Bio (CABA), Vistagen Therapeutics (VTGN), I-Mab (IMAB), Alto Neuroscience (ANRO), PyroGenesis Canada (PYRGF), Clearside Biomedical (CLSD), Pyxis Oncology (PYXS), and Rani Therapeutics (RANI). These companies are all part of the "pharmaceutical products" industry. MIRA Pharmaceuticals vs. Adagene Invizyne Technologies Cabaletta Bio Vistagen Therapeutics I-Mab Alto Neuroscience PyroGenesis Canada Clearside Biomedical Pyxis Oncology Rani Therapeutics MIRA Pharmaceuticals (NASDAQ:MIRA) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Which has higher valuation & earnings, MIRA or ADAG? MIRA Pharmaceuticals has higher earnings, but lower revenue than Adagene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$11.98M-$0.52-2.20Adagene$103.20K709.82-$18.95MN/AN/A Is MIRA or ADAG more profitable? Adagene's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -337.44% -280.58% Adagene N/A N/A N/A Does the MarketBeat Community believe in MIRA or ADAG? Adagene received 20 more outperform votes than MIRA Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave MIRA Pharmaceuticals an outperform vote while only 79.31% of users gave Adagene an outperform vote. CompanyUnderperformOutperformMIRA PharmaceuticalsOutperform Votes3100.00% Underperform VotesNo VotesAdageneOutperform Votes2379.31% Underperform Votes620.69% Does the media prefer MIRA or ADAG? In the previous week, Adagene had 3 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 5 mentions for Adagene and 2 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.43 beat Adagene's score of 0.96 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment MIRA Pharmaceuticals Positive Adagene Positive Do analysts recommend MIRA or ADAG? MIRA Pharmaceuticals currently has a consensus target price of $14.00, suggesting a potential upside of 1,122.71%. Adagene has a consensus target price of $8.00, suggesting a potential upside of 414.47%. Given MIRA Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe MIRA Pharmaceuticals is more favorable than Adagene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Adagene 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals and insiders believe in MIRA or ADAG? 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Comparatively, 21.2% of Adagene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, MIRA or ADAG? MIRA Pharmaceuticals has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Adagene has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. SummaryMIRA Pharmaceuticals beats Adagene on 9 of the 15 factors compared between the two stocks. Get MIRA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRA vs. The Competition Export to ExcelMetricMIRA PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.25M$6.82B$5.54B$7.99BDividend YieldN/A2.96%5.09%4.22%P/E Ratio-2.047.4322.6818.71Price / SalesN/A253.33405.96105.45Price / CashN/A65.8538.1834.62Price / Book3.826.606.844.31Net Income-$11.98M$143.41M$3.22B$248.10M7 Day Performance10.10%3.17%1.84%2.02%1 Month Performance20.78%5.52%3.19%3.60%1 Year Performance42.84%-2.82%16.30%5.11% MIRA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRAMIRA Pharmaceuticals2.9217 of 5 stars$1.16+2.1%$14.00+1,102.7%+39.1%$19.57MN/A-2.082Short Interest ↓ADAGAdagene2.9667 of 5 stars$1.43+0.4%$8.00+461.4%-32.0%$67.13M$103,204.000.00260Short Interest ↓News CoverageIZTCInvizyne TechnologiesN/A$10.73-11.0%N/AN/A$67.08MN/A0.00N/ACABACabaletta Bio3.0624 of 5 stars$1.31+3.1%$21.00+1,503.1%-89.9%$66.47MN/A-0.6150Positive NewsVTGNVistagen Therapeutics1.8144 of 5 stars$2.29+3.2%N/A-50.2%$66.09M$698,000.00-1.5540News CoveragePositive NewsIMABI-Mab2.762 of 5 stars$0.81-3.4%$5.50+578.6%-50.6%$66.06M$3.27M0.00380Short Interest ↑ANROAlto Neuroscience1.8408 of 5 stars$2.41+2.6%$15.40+539.0%-84.8%$65.24MN/A-0.95N/APYRGFPyroGenesis CanadaN/A$0.35+8.8%N/A-19.0%$64.59M$9.14M-5.7790CLSDClearside Biomedical2.0265 of 5 stars$0.83-1.0%$5.25+530.3%-33.1%$64.37M$1.66M-1.8530Upcoming EarningsNews CoveragePYXSPyxis Oncology1.383 of 5 stars$1.04-1.9%$9.20+784.6%-75.0%$64.05M$16.15M-1.0160RANIRani Therapeutics2.4879 of 5 stars$1.10-1.8%$12.33+1,021.2%-83.2%$63.23M$1.03M-1.04110Upcoming Earnings Related Companies and Tools Related Companies Adagene Competitors Invizyne Technologies Competitors Cabaletta Bio Competitors Vistagen Therapeutics Competitors I-Mab Competitors Alto Neuroscience Competitors PyroGenesis Canada Competitors Clearside Biomedical Competitors Pyxis Oncology Competitors Rani Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIRA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MIRA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MIRA Stock Free MIRA Stock Alerts